This study is looking at how different education plans for monitoring ketones (substances produced when the body burns fat for energy) can help people with Type 1 Diabetes (T1D) who are taking a medication called sotagliflozin. Sotagliflozin is an SGLT-2 inhibitor, a type of drug that can increase the risk of diabetic ketoacidosis (DKA), a serious condition. Researchers want to see if a special education plan using continuous ketone monitoring can better prevent DKA compared to a general education plan. You might be able to join if you are 18 to 40 years old, have Type 1 Diabetes, and your HbA1c (a measure of blood sugar control) is less than 9%. The study will measure how many ketone events (when ketone levels are high) occur over 6 months to see if the special education plan is effective. The study is currently unclear on its recruitment status.

Study design

This is an interventional study planning to enroll 75 participants. It will compare a special education plan with continuous ketone monitoring to a general education plan.

What's involved

Participants will be asked to take the SGLT-2 inhibitor (sotagliflozin) and will undergo an Insulin Withdrawal Test (IWT) while being monitored.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, ketone events, will be measured at 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.